RedHill Sells Talicia Rights for $10M
Ticker: RDHL · Form: 6-K · Filed: Mar 14, 2024 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Mar 14, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: asset-sale, licensing, commercialization
TL;DR
RedHill sells Talicia US rights to Montrose for $10M upfront + milestones/royalties.
AI Summary
RedHill Biopharma Ltd. announced on March 14, 2024, that it has entered into a definitive agreement to sell its U.S. commercialization rights for Talicia to Montrose Pharmaceuticals, LLC for an upfront payment of $10 million. The agreement also includes potential milestone payments and royalties.
Why It Matters
This sale provides RedHill Biopharma with immediate capital, which can be used for operational needs and potentially to advance its other pipeline candidates.
Risk Assessment
Risk Level: medium — The company's financial health and future success are still dependent on the successful development and commercialization of its remaining pipeline and the terms of the deal with Montrose.
Key Numbers
- $10.0M — Upfront Payment (Received by RedHill Biopharma from Montrose Pharmaceuticals for U.S. commercialization rights of Talicia.)
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Seller
- Montrose Pharmaceuticals, LLC (company) — Buyer
- Talicia (drug) — Product
- $10 million (dollar_amount) — Upfront payment
- March 14, 2024 (date) — Announcement date
FAQ
What are the key terms of the agreement between RedHill Biopharma and Montrose Pharmaceuticals?
RedHill Biopharma will receive an upfront payment of $10 million, with potential for additional milestone payments and royalties.
What specific asset is RedHill Biopharma selling rights to?
RedHill Biopharma is selling the U.S. commercialization rights for its drug Talicia.
Who is the acquiring party for the Talicia rights?
Montrose Pharmaceuticals, LLC is acquiring the U.S. commercialization rights for Talicia.
When was this agreement announced?
The agreement was announced on March 14, 2024.
What is the potential upside for RedHill Biopharma beyond the upfront payment?
RedHill Biopharma is eligible to receive potential milestone payments and royalties on future sales of Talicia.
Filing Stats: 619 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-03-14 16:03:54
Key Financial Figures
- $1.00 — s ("ADSs") had closed below the minimum $1.00 per share requirement for continued lis
Filing Documents
- zk2431147.htm (6-K) — 13KB
- 0001178913-24-000953.txt ( ) — 14KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: March 14, 2024 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer